Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

Srdan Verstovsek, MD PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Elisa Rumi, MD, Elisabetta Gattoni, MD, Lisa Pieri, MD PhD, Haifeng Zhang, PhD, Mario Cazzola, MD, Hagop M. Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1847.

https://doi.org/10.1182/blood.V124.21.1847.1847

Published: 2014

Journal Articles

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

Srdan Verstovsek, MD, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter J. Rosen, MD, Shui He, PhD, Nancy Contel, DVM, Bijoyesh Mookerjee, MD, FACP, Elisa Rumi, MD, Elisabetta Gattoni, MD, Lisa Pieri, MD, Mario Cazzola, MD, Hagop M. Kantarjian, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2012) 120 (21): 804.

https://doi.org/10.1182/blood.V120.21.804.804

Published: 2012

Journal Articles

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srdan Verstovsek, MD, PhD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui, Alessandro Vannucchi

Blood (2009) 114 (22): 311.

https://doi.org/10.1182/blood.V114.22.311.311

Published: 2009

Journal Articles

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD, Elisabetta Gattoni, MD, Elisabetta Antonioli, MD, Costanza Bogani, PhD, Lorenzo Tozzi, BSc, Lisa Pieri, MD, Alberto Bosi, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD

Blood (2009) 114 (22): 307.

https://doi.org/10.1182/blood.V114.22.307.307

Published: 2009

Journal Articles

High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly.

Vittorio Rosti, MD, Elisa Bonetti, Gaetano Bergamaschi, MD, Rita Campanelli, PhD, Elisabetta Gattoni, MD, Sonia Lo Po, Umberto Magrini, MD, Margherita Massa, PhD, Alessandro Vannucchi, MD, Gianluca Viarengo, MD, Paola Guglielmelli, MD, Massimo Primignani, MD, Giovanni Barosi, MD

Blood (2009) 114 (22): 309.

https://doi.org/10.1182/blood.V114.22.309.309

Published: 2009

Journal Articles

Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.

Francesco Passamonti, Elisabetta Gattoni, MD, Francisco Cervantes, Heinz Gisslinger, MD, Ronald Paquette, MD, Robert P Gale, Srdan Verstovsek, MD, PhD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 1904.

https://doi.org/10.1182/blood.V114.22.1904.1904

Published: 2009

Journal Articles

Kinetics of CD34+ Cells in the Peripheral Blood of Patients with Primary Myelofibrosis Undergoing Splenectomy

Rita Campanelli, PhD, Margherita Massa, PhD, Elisa Bonetti, Gianluca Viarengo, MD, Vittorio Rosti, MD, Elisabetta Gattoni, MD, Enza Moretti, Gaetano Bergamaschi, MD, Laura Villani, PhD, Marco Lucioni, MD, Laura Bandiera, MD, Roberta Riboni, PhD, Gianni Barosi, MD

Blood (2008) 112 (11): 3725.

https://doi.org/10.1182/blood.V112.11.3725.3725

Published: 2008

Journal Articles

A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2 V617F Positive Chronic Myeloproliferative Neoplasms

Alessandro Rambaldi, Chiara Maria Dellacasa, Silvia Salmoiraghi, Orietta Spinelli, Maria Luisa Ferrari, Elisabetta Gattoni, MD, Paola Guglielmelli, Alessandro M. Vannucchi, Giovanni Barosi, Tiziano Barbui

Blood (2008) 112 (11): 100.

https://doi.org/10.1182/blood.V112.11.100.100

Published: 2008

Journal Articles

A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.

Giovanni Barosi, MD, Elisabetta Gattoni, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD, Alessandro Rambaldi, MD, Lewis Silverman, MD, Judith Goldberg, MD, Roberto Marchioli, MD, Ronald Hoffman, MD

Blood (2007) 110 (11): 3540.

https://doi.org/10.1182/blood.V110.11.3540.3540

Published: 2007

NARROW

Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea

Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET MF).

High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly.

Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.

Kinetics of CD34+ Cells in the Peripheral Blood of Patients with Primary Myelofibrosis Undergoing Splenectomy

A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2 V617F Positive Chronic Myeloproliferative Neoplasms

A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only